Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States

SETTING: A large randomized controlled trial recently showed that for treating latent tuberculous infection (LTBI) in persons at high risk of progression to tuberculosis (TB) disease, a 12-dose regimen of weekly rifapentine plus isoniazid (3HP) administered as directly observed treatment (DOT) can b...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Tuberc Lung Dis
Glavni autori: Shepardson, D., Marks, S. M., Chesson, H., Kerrigan, A., Holland, D. P., Scott, N., Tian, X., Borisov, A. S., Shang, N., Heilig, C. M., Sterling, T. R., Villarino, M. E., Mac Kenzie, W. R.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5451112/
https://ncbi.nlm.nih.gov/pubmed/24200264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/ijtld.13.0423
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items